Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIxico Regulatory News (IXI)

Share Price Information for Ixico (IXI)

Share Price is delayed by 15 minutes
Get Live Data
8.65    0.00 (0.00%)
Bid:
0.00
Ask:
0.00
Spread: 0.70 (8.434%)
Market Cap: £18.86m
IXI Live PriceLast checked at - London Stock Exchange

Intraday Ixico Share Chart

Holding(s) in Company

11 Jun 2007 11:56

Phytopharm PLC11 June 2007 TR-1: notification of major interests in shares 1. Identity of the issuer or Phytopharm plcthe underlying issuer of --------------------existing shares to which votingrights are attached:-------------------------------2. Reason for the notification (please tick the appropriate box or boxes)-------------------------------------------- -------An acquisition or disposal of voting rights (X) An acquisition or disposal of financial instruments which may result in the ( )acquisition of shares already issued to which voting rights are attached ---------------------------------------------------An event changing the breakdown of voting rights ( )-------------------------------------------- -------Other (please specify):___________________________________________ ( )-------------------------------------------- -------3. Full name of person(s) AXA S.a, 25 Avenue Matignon, 75008 Paris and its group of companiessubject to the notification --------------------obligation:-------------------------------4. Full name of shareholder(s)(if different from 3.): ---------------------------------------------------5. Date of the transaction (and 07/06/2007date on which the threshold is --------------------crossed or reached ifdifferent)-------------------------------6. Date on which issuer 08/06/2007notified: ---------------------------------------------------7. Threshold(s) that is/arecrossed or reached: ---------------------------------------------------8. Notified details:------------------------------- -------------------- A: Voting rights attached to sharesClass/type Situation previous to the Resulting situation after the triggeringof shares Triggering transaction transactionif possibleusing the Number of Number of Number of Number of voting % of votingISIN CODE Shares Voting shares rights rights Rights Direct Direct x Indirect xi Direct IndirectOrdinary 1Pence 3,328,148 3,328,148 11,000 11,000 3,327,148 0.02 5.98GB000686972 B: Financial InstrumentsResulting situation after the triggering transactionType of Expiration Exercise/ Number of voting rights that may % offinancial date Conversion be acquired if the instrument is votinginstrument Period/ Date exercised/ converted. rights Total (A+B)Number of voting rights % of voting rights3,338,148 6.00% 9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable: Name of the Company/Fund Number of Shares % of issued share capitalAXA UK Investment Co ICVC UKSmaller Companies Fund 620 0.00111IndirectSun Life Pensions ManagementLtd 11,000 0.01978DirectAXA Framlington Equity Income 1,851,612 3.32986IndirectAXA Framlington Biotech 1,052,631 1.89301IndirectFramlington onshore privateclients 396,483 0.71302IndirectFramlington onshore privateclients 25,802 0.04640Indirect Total direct 11,000 0.01978 Total Indirect 3,327,148 5.98340 Total 3,338,148 6.00318 Proxy Voting:10. Name of the proxy holder:11. Number of voting rights proxy holder will cease to hold:12. Date on which proxy holder will cease to hold voting rights: 13. Additional Notification using the total voting rights figure ofinformation: 55,606,30914. Contact name: Zoe McGowan, Company Secretary15. Contacttelephonenumber: 01480 437697 This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
8th Jun 20267:00 amRNSScientific advisors & partners update
22nd May 20267:00 amRNS-RCompany presentation at Mello 2026
21st May 20267:00 amRNSContract win and contract extension
19th May 20267:00 amRNSInterim results for six months ending 31/03/2026
12th May 20267:00 amRNSIXICO Updates AI Neuroimaging Platform
28th Apr 20262:31 pmRNSHolding(s) in Company
28th Apr 20261:50 pmRNSHolding(s) in Company
28th Apr 202611:45 amRNSHolding(s) in Company
28th Apr 202610:49 amRNSHolding(s) in Company
27th Apr 20264:02 pmRNSHolding(s) in Company
27th Apr 20263:57 pmRNSHolding(s) in Company
27th Apr 20263:55 pmRNSHolding(s) in Company
27th Apr 20261:51 pmRNSHolding(s) in Company
27th Apr 202611:13 amRNSHolding(s) in Company
24th Apr 20263:30 pmRNSHolding(s) in Company
22nd Apr 202612:40 pmRNSIssue of Equity
21st Apr 20267:00 amRNSTrading Update
16th Apr 202612:01 pmRNSResult of GM and Update on Issue of Equity
7th Apr 20261:14 pmRNSResult of Retail Offer
31st Mar 20267:01 amRNSRetail Offer
31st Mar 20267:00 amRNSPlacings and Subscription
26th Mar 20267:00 amRNSCollaboration with Medidata
26th Feb 20267:00 amRNSValidation of Neuroimaging Technology Platform
12th Feb 20268:48 amRNSCorrection: c.£1.5 million Contract Extension
12th Feb 20267:00 amRNSc.£1.5 million Contract Extension
5th Feb 20267:00 amRNSAppointment of Chief Commercial Officer
23rd Jan 20265:05 pmRNSResults of AGM
9th Dec 20257:05 amRNSShare option award
9th Dec 20257:00 amRNSFinancial Results for year ended 30 September 2025
1st Dec 20257:00 amRNSOperational Update
27th Nov 20257:00 amRNSNotice of 2025 Full Year Results and IMC
17th Nov 20257:00 amRNSClinical Trial Contract Win
3rd Nov 20252:30 pmRNSCapital Markets Day Presentation and Video
16th Oct 20257:00 amRNSTrading Update
15th Oct 20257:00 amRNSNew contract win and contract extension
30th Sep 20257:00 amRNSNotice of Capital Markets Day
12th Aug 20257:00 amRNSContract Win
22nd Jul 20257:00 amRNSStrategic Data Partnership with GAP
17th Jul 20257:00 amRNSTrading Update
13th Jun 20258:03 amRNSShare option awards and PDMR Dealing
10th Jun 20257:00 amRNSFDA Clearance of Alzheimer's Diagnostic Biomarker
20th May 20256:00 pmRNSHolding(s) in Company
20th May 20257:00 amRNSHalf-year Report
8th May 202511:30 amRNSHolding(s) in Company
6th May 20257:00 amRNSNotice of Interim Results & Investor Presentation
16th Apr 20257:00 amRNSTrading Update
27th Feb 20257:00 amRNSContract Win
12th Feb 20257:00 amRNSFurther Validation of IXICO’s AI Imaging Platform
7th Feb 20253:00 pmRNSIssue of share options and PDMR dealing
24th Jan 20252:16 pmRNSResult of AGM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.